Colestyramine(Colestyramine) - 药物靶点：FABP6_在研适应症：胆汁酸吸收不良（BAM）_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Colestyramine

靶点

FABP6

作用机制

FABP6调节剂(胆汁酸结合蛋白调节剂)

治疗领域

消化系统疾病内分泌与代谢疾病

在研适应症

胆汁酸吸收不良（BAM）

非在研适应症

进行性家族性肝内胆汁淤积症 1胆汁性肝硬化

原研机构

Albireo Pharma, Inc.

在研机构

Albireo Pharma, Inc.

非在研机构

Albireo AB

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Colestyramine 相关的临床试验

NCT02078856 / Completed临床2期

A Phase II, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of A3384 in Patients With Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)

The purpose of this trial is to determine the efficacy and safety of A3384 administered to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD).

开始日期2014-03-01

申办/合作机构

Albireo AB

EUCTR2013-002924-17-GB / Not yet recruiting临床2期

A double-blind, randomized, placebo-controlled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD) - A3384 in BAM/BAD

开始日期2013-12-24

申办/合作机构

Albireo AB

NCT02963077 / Completed临床1期

A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects

The primary objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of A4250 after single or multiple oral doses in healthy subjects. In addition, will evaluate A4250 in combination with cholestyramine.

开始日期2013-07-01

申办/合作机构

Albireo AB

100 项与 Colestyramine 相关的临床结果

登录后查看更多信息

100 项与 Colestyramine 相关的转化医学

登录后查看更多信息

100 项与 Colestyramine 相关的专利（医药）

登录后查看更多信息

69

项与 Colestyramine 相关的文献（医药）

2021-12-01·Journal of Clinical Pharmacy and Therapeutics

Acute teriflunomide overdose with relatively mild symptoms: A case report

作者: Mian, Paola ; Drie‐Pierik, Regine J. H. M. ; Haaften, W. Tobias ; Assink, Marijke

WHAT IS KNOW AND OBJECTIVETeriflunomide is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis.CASE SUMMARYWe present a rare intoxication with a high dose (672 mg) of teriflunomide. According to its product label, the only known treatment is the administration of colestyramine and activated carbon (charcoal). No serious adverse events occurred during the time the patient was admitted (<24 h). No long-term overdose-related symptoms or complaints were reported.WHAT IS NEW AND CONCLUSIONThe fact that after the acute overdose both adverse events and laboratory parameters were acceptable, prescribing colestyramine and activated carbon, as well as monitoring of laboratory parameters such as full blood count, liver and kidney values and QTc, seems sufficient during the early stage (<24 h after intake) of teriflunomide overdose.

2021-07-01·Hepatology1区 · 医学

Long‐Term Colestyramine Treatment Prevents Cholestatic Attacks in Refractory Benign Recurrent Intrahepatic Cholestasis Type 1 Disease

1区 · 医学

Article

作者: Weber, Susanne N ; Lammert, Frank ; Berg, Thomas ; Ziagaki, Athanasia ; Koukoulioti, Eleni

A polemic paper is given by Thomas.This article is discuss about Long-Term Colestyramine Treatment Prevents Cholestatic Attacks in Refractory Benign Recurrent Intrahepatic Cholestasis Type 1 Disease.However, the fact that the relief of pruritus and normalization of biochem. parameters were observed immediately after increasing colestyramine dose, as well as the longstanding clin. remission, make this scenario less likely.

2020-09-01·Journal of Clinical Lipidology2区 · 医学

Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature

2区 · 医学

Review

作者: Yap, Fabian ; Tan, Teng Hong ; Sreedharan, Aravind Venkatesh ; Pek, Sharon Li Ting ; Tavintharan, Subramaniam

Severe familial hypercholesterolemia (SFH) is characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) and severe early-onset cardiovascular disease if left untreated. We report on the decade-long therapeutic journey of a 15-year-old boy with SFH due to a severe compound heterozygous genotype. He presented at the age of 5 years with widespread xanthomas and LDL-C of 17.4 mmol/L. He was diagnosed with SFH, initially treated with colestyramine that was subsequently combined with simvastatin. At the age of 12 years, he was diagnosed to have supravalvular aortic stenosis and ezetimibe/atorvastatin was introduced in place of colestyramine/simvastatin. At the age of 14 years, he received triple therapy with evolocumab, initially at the recommended dose of 420 mg monthly and then reduced to 140 mg biweekly. Currently at the age of 15 years, he is on atorvastatin 40 mg ON, ezetimibe 10 mg OM, and evolocumab 140 mg biweekly, achieving LDL-C levels of 2.4 mmol/L. Genetic testing identified compound heterozygous mutations in the LDL receptor genes [c.(940 + 1_941-1) (1845 + 1_1846-1)dup] and exon 12, nucleotide c.1747 C > T, amino acid p.(His583Tyr). Medical management without lipoprotein apheresis can achieve target LDL-C in children with SFH. Our patient, who developed supravalvular aortic stenosis at the age of 12 years, needed early aggressive treatment when SFH guidelines and newer drugs for young children were unavailable. Our patient demonstrated that 140 mg biweekly of evolocumab has the same cholesterol-lowering effect as the recommended 420 mg monthly dose.

100 项与 Colestyramine 相关的药物交易

登录后查看更多信息